Oncologia Medica, Fondazione Policlinico A. Gemelli-IRCCS, Università Cattolica del S. Cuore, Rome, Italy.
Oncologia Medica, Istituto Nazionale dei Tumori-IRCCS, Milan, Italy.
Future Oncol. 2021 May;17(14):1749-1759. doi: 10.2217/fon-2020-1181. Epub 2021 Jan 19.
To help to remove misperception of an appropriate position of trifluridine/tipiracil (FTD/TPI) in the treatment of metastatic colorectal cancer. The RAND Corporation/UCLA Appropriateness Method was used by a panel of Italian experts to develop recommendations concerning daily practice with FTD/TPI. Forty-three clinical scenarios were discussed in two rounds and the resulting statements were rated as appropriate, uncertain or inappropriate, according to the median score. Several topics were dealt with, covering the profile of eligible patients, therapeutic options beyond the second line, the practice of treatment with FTD/TPI, evaluation and efficacy and toxicity, as well as costs and compliance. FTD/TPI is an important therapeutic resource in refractory metastatic colorectal cancer that combines manageability and safety.
为了帮助消除人们对三氟尿苷/替匹嘧啶（FTD/TPI）在转移性结直肠癌治疗中适当地位的误解。一个意大利专家小组使用 RAND 公司/UCLA 适宜性方法制定了有关 FTD/TPI 日常实践的建议。在两轮讨论中，共讨论了 43 个临床情况，并根据中位数评分将产生的陈述评定为适当、不确定或不适当。涉及了多个主题，涵盖了合格患者的特征、二线以上的治疗选择、FTD/TPI 的治疗实践、评估和疗效以及毒性，以及成本和顺应性。FTD/TPI 是难治性转移性结直肠癌的重要治疗资源，兼具可管理性和安全性。
